Skip to main content
Optimising biotech funding whitepaper series
Read the whitepapers
Pushing boundaries in idiopathic pulmonary fibrosis clinical research
Read the whitepaper
2023 biotech sector survey
Navigating biotech's challenges and embracing a promising tomorrow
Read the report
Navigating the regulatory labyrinth of technology in decentralised clinical trials
Read the whitepaper
EMA guideline on computerised systems and electronic data in clinical trials
Key considerations on the impact of the new framework of globally applicable standards.
COVID-19 vaccines: Post-authorisation safety surveillance
Challenges in assessing long term effects of COVID vaccines.
Exploring partnership culture and its impact on outsourcing and operational strategy
Actionable insights, proven strategies, and expert recommendations.
Considerations for DTx clinical trials in CNS indications
Successful digital therapeutic clinical trials.
Featured Solutions
Biotech
ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.
Early Clinical and Bioanalytical Solutions
Innovative early clinical solutions that will advance your drug development strategy.
Medical Imaging
Expert medical imaging solutions for all stages of clinical research enabling improved decision making, increased efficiency and reduced trial costs.
Site & Patient Solutions
Transforming recruitment through patient-centric trials and real-world, real-time data.
Market Access
Expertise in mission-critical pricing, market access, and reimbursement. 
Functional outsourcing
ICON is the world's largest provider of FSP services.
Webinars
Strategies to optimise commercialisation of oncology treatments for younger adults
25 January 2024. Register today.
Streamlining IRT in clinical trials: Simplify, optimise, succeed
15 February 2024. Register today.
The future of pharmacovigilance: Exploring automation and AI in literature surveillance
22 February 2024. Register today.
ICON

ICON Environmental, Social & Governance (ESG) including 2021 report.